Hypoparathyroidism (HPT) is a rare endocrine condition characterized by fluctuations in parathyroid hormone (PTH) levels, which can lead to significant health-related quality of life (HRQOL) impairments. This study aimed to develop patient-reported outcome (PRO) measures to assess the symptomatic and HRQOL impacts of HPT and support the findings from the full CE interview stage.

**RESULTS**

The targeted interview sample was recruited by 88 invitations in 8 countries: the United Kingdom (English), France (French), Belgium (French/Belgian Dutch), Germany (German), Spain (Spanish), Italy (Italian), Greece (Greek), and Portugal (Portuguese). Each country had 8-10 interviews per language, except for 5 CE interviews in the United Kingdom and 4 in France.

The instruments' depression scores correlated with health status, with potential modifiers such as comorbidities, in addition to other symptoms. The instruments' anxiety, worry/stress, and depression/low mood scores also correlated with the patient's perceptions of treatment availability in mind.

**CONCLUSIONS**

The rigorous development process yielded 2 HPT-specific PRO measures: the HPT-DD-SE (Draft, V3.0) and HPT-LIQ (Draft, V4.0). These measures-evaluation彭了 clarity, understandability, and comprehensiveness as the TA and expert review.

**REFERENCES**


**CONTACT INFORMATION**

Astellas Pharma USA
1225 Leatherock Lane
Axton, TX 75744
USA

Tel: +1 214-283-8000
Fax: +1 214-747-8996

Astellas Pharma Global
1-17-1 Shioiri, Minato-ku
Tokyo, 105-8068 Japan

Tel: +81 3 3405 5000
Fax: +81 3 3405 5199